Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Fabien, Calcagno"'
Autor:
Emeline Orillard, Julie Henriques, Dewi Vernerey, Hamadi Almotlak, Fabien Calcagno, Francine Fein, Serge Fratté, Marine Jary, Elodie Klajer, Angelique Vienot, Christophe Borg, Stefano Kim
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundStudies have reported a beneficial role of the addition of trastuzumab to platin-5-FU based chemotherapy in first-line advanced HER2 positive gastroesophageal adenocarcinoma (GEA). However, the effect of taxanes combined with platin-5FU + t
Externí odkaz:
https://doaj.org/article/57e113288c4c4987b99eabfc7487b9b2
Autor:
Guillaume Mouillet, Marie-Justine Paillard, Tristan Maurina, Dewi Vernerey, Thierry Nguyen Tan Hon, Hamadi Almotlak, Ulrich Stein, Fabien Calcagno, Diane Berthod, Elise Robert, Aurelia Meurisse, Antoine Thiery-Vuillemin
Publikováno v:
Trials, Vol 19, Iss 1, Pp 1-9 (2018)
Abstract Background Sunitinib is a tyrosine kinase inhibitor approved in the first-line metastatic renal cell carcinoma (MRCC) setting at the dose of 50 mg daily for 4 weeks followed by a pause of 2 weeks. Due to toxicity, this standard schedule (50
Externí odkaz:
https://doaj.org/article/c2f4c7276ffa44faa478a7ca6bf2d755
Autor:
Fabien Calcagno, Sabrina Lenoble, Zaher Lakkis, Thierry Nguyen, Samuel Limat, Christophe Borg, Marine Jary, Stefano Kim, Virginie Nerich
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 2016, Iss 10, Pp 59-66 (2016)
Externí odkaz:
https://doaj.org/article/4d40783b7b7d481485ea32e0c8ca7816
Autor:
Arthur Petat, Eric Dansin, Fabien Calcagno, Laurent Greillier, Eric Pichon, Mallorie Kerjouan, Christelle Clement-Duchene, Bertrand Mennecier, Virginie Westeel, François Thillays, Xavier Quantin, Youssef Oulkhouir, Luc Thiberville, Charles Ricordel, Vincent Thomas De Montpreville, Lara Chalabreysse, Véronique Hofman, Thierry Molina, Pierre Fournel, Laurence Bigay Game, Benjamin Besse, Nicolas Girard
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2022, 162, pp.118-127. ⟨10.1016/j.ejca.2021.11.028⟩
European Journal of Cancer, 2022, 162, pp.118-127. ⟨10.1016/j.ejca.2021.11.028⟩
Thymic carcinomas are aggressive and difficult to treat a subset of thymic epithelial tumours that represent a heterogeneous group of rare intrathoracic malignancies. The treatment strategy of thymic carcinomas is based on whether surgical resection
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::424d7491517fd77cd2fa4fc0b6e13729
https://doi.org/10.1016/j.ejca.2021.11.028
https://doi.org/10.1016/j.ejca.2021.11.028
Autor:
Ziyad Alsugair, Fabien Calcagno, Jean-Christophe Lifante, Francoise Descotes, Jonathan Lopez, Nikolaos Zirganos, Céline Charon-Barra, Alexandra Meurgey, Myriam Decaussin-Petrucci
We report a case of primary thyroid rhabdomyosarcoma in a 61-year-old woman. Histologically, the neoplasm was composed of sheets of pleomorphic or spindle-shaped cells with eosinophilic cytoplasm and few large and very pleomorphic cells admixed with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87d868366bed1928118eaedb2dfade77
https://doi.org/10.21203/rs.3.rs-2483550/v1
https://doi.org/10.21203/rs.3.rs-2483550/v1
Autor:
Christophe Borg, Laura Mansi, Cristian Villanueva, Stefano Kim, Elsa Curtit, Oumelkheir Djoumakh, Amélie Anota, Guillaume Eberst, Sophie Paget-Bailly, Guillaume Mouillet, Antoine Falcoz, Marine Jary, Hamadi Almotlak, Xavier Pivot, Olivier Adotevi, J. Fritzsch, Astrid Pozet, Nathalie Meneveau, Fabien Calcagno, Angélique Vienot, Virginie Westeel, P. Jacoulet
Publikováno v:
Quality of Life Research. 30:3255-3266
Routine Electronic Monitoring of Health-Related Quality of Life (HRQoL) (REMOQOL) in clinical care with real-time feedback to physicians could help to enhance patient-centered care. We evaluated the feasibility of REMOQOL in the French context in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57e6ad0d05383b537c1bf726e8bf68e4
https://doi.org/10.1007/s11136-020-02721-0
https://doi.org/10.1007/s11136-020-02721-0
Autor:
Fabien Calcagno, Thierry Nguyen, Erion Dobi, Cristian Villanueva, Elsa Curtit, Stefano Kim, Philippe Montcuquet, François Kleinclauss, Xavier Pivot, Antoine Thiery-Vuillemin
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 2013, Iss 7, Pp 1-12 (2012)
Externí odkaz:
https://doaj.org/article/2c07c35110464a898a790e14bfb88209
Autor:
Guillaume Mouillet, T. Nguyen Tan Hon, Fabien Calcagno, Noémie Gassian, Thibaut Murez, A. Frontczak, Antoine El Kaddissi, Ulrich Stein, Johann Barkatz, Tristan Maurina, Hamadi Almotlak, Antoine Thiery-Vuillemin
Publikováno v:
Bulletin du Cancer. 107:S17-S23
Resume Les cancers du penis sont rares, representes en grande majorite par le carcinome epidermoide, le virus HPV y est associe dans 30 a 40 % des cas. A un stade localement avance ou metastatique, la prise en charge de premiere ligne repose sur une
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6819c5bbdf84d82a06f3e77312ae7e02
https://doi.org/10.1016/s0007-4551(20)30274-5
https://doi.org/10.1016/s0007-4551(20)30274-5
Autor:
Elodie Klajer, Marine Jary, Angélique Vienot, Aurélia Meurisse, Francine Fein, Clément Bolognini, Syrine Abdeljaoued, Hortense Chevalier, Dewi Vernerey, Meher Nasri, Anthony Turpin, Stefano Kim, Hamadi Almotlak, Thierry Nguyen, Christophe Borg, Elisabeta Gherga, Fabien Calcagno, Christelle d’Engremont
Publikováno v:
World Journal of Gastrointestinal Oncology. 12:332-346
FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bd22f47433905a42072504e54f296e5
https://doi.org/10.4251/wjgo.v12.i3.332
https://doi.org/10.4251/wjgo.v12.i3.332
Autor:
Olivier Adotevi, Guillaume Mouillet, Laura Boullerot, Caroline Laheurte, Harmonie Simonin, Christophe Borg, Marion Jacquin, Anna Legros, Antoine Thiery-Vuillemin, Fabien Calcagno, Thierry Nguyen
Publikováno v:
International Journal of Cancer. 147:1199-1205
Biochemical recurrence (BCR) occurs in up to 40% of prostate cancer patients after prostatectomy. In our study, we performed an immune monitoring study in 20 prostate cancer patients with BCR previously treated with metronomic cyclophosphamide (mCTX)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3799e591370d4bc5c53408b48b1576eb
https://doi.org/10.1002/ijc.32803
https://doi.org/10.1002/ijc.32803